机构:[1]Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, Yunnan, China.[2]Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.内科科室肾脏内科昆明医科大学附属第一医院[3]Department of Nephrology, The Third People's Hospital of Yunnan Province, Kunming, Yunnan, P.R. China.
The understanding concerning the function of immune system in cancer has achieved considerable advance with time passes by. Manipulating genetically engineered immune cells were investigated as a novel strategy for treating cancer. Chimeric antigen receptors (CARs) are recombinant protein molecules by merging the exquisite targeting the potent cytotoxicity of T cells and specificity of monoclonal antibodies and, which could trigger serial cascades of signal transduction and thereby activate T cells to directly destroy the tumor cells. Manufacturing CAR-modified T lymphocytes were successfully implemented in treating cancer derived from they could specifically retarget tumor-associated antigens, causing effective elimination of tumor cells, which spurred the optimization and development of new CAR-T cell technology. The advancement of synthetic biology methodologies of cell therapy in CAR-T would ultimately provide us with a much safer, reliable and efficient modality to against cancer. This review primarily described the emergence, development and application of cell therapy in CAR-T, then discuss the side effects and the potential factors of tumor reccurrence caused by CAR-T cell therapy, in addition to the corresponding countermeasure concerning complications.
基金:
This work was supported by the National
Natural Science Foundation of China (No. 81860423
and 81460649). and The fund of Yun-nan Provincial
Clinical Center of Hepato-biliary-pancreatic Diseases,
The Medical Leading Talent Project of Yunnan
Province (No. L-201606).
第一作者机构:[1]Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, Yunnan, China.[2]Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.[3]Department of Nephrology, The Third People's Hospital of Yunnan Province, Kunming, Yunnan, P.R. China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Li Ling-Lin,Yuan Hong-Ling,Yang Yu-Qiong,et al.A brief review concerning Chimeric Antigen Receptors T cell therapy.[J].JOURNAL OF CANCER.2020,11(18):5424-5431.doi:10.7150/jca.46308.
APA:
Li Ling-Lin,Yuan Hong-Ling,Yang Yu-Qiong,Wang Lin&Zou Ren-Chao.(2020).A brief review concerning Chimeric Antigen Receptors T cell therapy..JOURNAL OF CANCER,11,(18)
MLA:
Li Ling-Lin,et al."A brief review concerning Chimeric Antigen Receptors T cell therapy.".JOURNAL OF CANCER 11..18(2020):5424-5431